TrialNature communications2026

Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR): a single-arm phase II trial.

Xiaobin Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.